We are pleased to announce that Updata Partners VII has invested in Delaware-based TJM Labs as part of the Company’s recent $75 million Series B financing. TJM Labs enables pharmacies to automate high-volume workflows through AI agents.
Pharmacies are operating in an increasingly challenging environment, facing persistent labor shortages, rising prescription volumes, and growing administrative complexity. As these pressures continue to mount, pharmacy teams are being asked to do more with fewer resources, while many critical processes remain manual and time intensive. TJM addresses these challenges through AI agents purpose-built for pharmacy operations, automating repetitive, non-clinical workflows that create bottlenecks. The platform drives measurable efficiency gains while allowing pharmacists to focus their efforts on higher-value patient care.
The Company’s growth and market-leading position reflect these compelling dynamics. TJM’s AI agents process more than 500,000 tasks every day across more than 450 pharmacies, ranging from independent pharmacies to enterprise organizations. We see significant opportunity to support the Company’s continued investment in AI, its expansion across the sector, and its long-term vision of becoming the foundational platform for modern pharmacy operations.
TJM Labs is led by Founder and CEO Jonathan Adly, whose unique background in both pharmacy and engineering provided the foundation for the business. We look forward to partnering with Jonathan and the TJM team as the Company enters its next phase of growth.
The Company’s press release can be found here.